Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Shares Outstanding (Diluted Average) (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $107.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 1171.0% to $107.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $107.4 million, a 1171.0% increase, with the full-year FY2024 number at $7.7 million, up 145.18% from a year prior.
  • Shares Outstanding (Diluted Average) was $107.4 million for Q3 2025 at Plus Therapeutics, down from $209.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $209.2 million in Q2 2025 to a low of $1.5 million in Q2 2022.
  • A 5-year average of $24.8 million and a median of $7.7 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 89.21% in 2023, then skyrocketed 1846.91% in 2025.
  • Plus Therapeutics' Shares Outstanding (Diluted Average) stood at $11.0 million in 2021, then crashed by 84.03% to $1.8 million in 2022, then soared by 79.45% to $3.1 million in 2023, then skyrocketed by 145.18% to $7.7 million in 2024, then soared by 1295.04% to $107.4 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Shares Outstanding (Diluted Average) are $107.4 million (Q3 2025), $209.2 million (Q2 2025), and $14.6 million (Q1 2025).